HROW Stock Overview
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Harrow Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.50 |
| 52 Week High | US$17.84 |
| 52 Week Low | US$5.40 |
| Beta | 0.23 |
| 1 Month Change | 21.61% |
| 3 Month Change | 50.47% |
| 1 Year Change | 124.36% |
| 3 Year Change | 153.62% |
| 5 Year Change | 993.75% |
| Change since IPO | 102.34% |
Recent News & Updates
Recent updates
Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Harrow Health prices 8.625% senior notes due 2026
Jun 15Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage
May 28Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings
May 18Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 11Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years
Mar 08Is Harrow Health (NASDAQ:HROW) Using Debt Sensibly?
Feb 01
How Is Harrow Health's (NASDAQ:HROW) CEO Compensated?
Dec 28Harrow Health: Eye Care On The Rise
Dec 07Could The Harrow Health, Inc. (NASDAQ:HROW) Ownership Structure Tell Us Something Useful?
Dec 02Harrow Health EPS of $0.32
Nov 09Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 18.8% | -0.5% | 1.7% |
| 1Y | 124.4% | 4.6% | -9.6% |
Return vs Industry: HROW exceeded the US Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: HROW exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HROW is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: HROW's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 182 | Mark Baum | https://www.harrowinc.com |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Harrow Health, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market Cap | US$521.33m |
| Earnings (TTM) | -US$22.56m |
| Revenue (TTM) | US$88.45m |
5.9x
P/S Ratio-23.1x
P/E RatioIs HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$88.45m |
| Cost of Revenue | US$24.30m |
| Gross Profit | US$64.16m |
| Other Expenses | US$86.72m |
| Earnings | -US$22.56m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 72.53% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 8,380.4% |
How did HROW perform over the long term?
See historical performance and comparison